Search Results - "Cheng, Christine M"

Bevacizumab for Neovascular Ocular Diseases by Lynch, Shalini S, Cheng, Christine M

“…Objective: To review the efficacy and safety of off-label use of bevacizumab for neovascular ocular diseases. Data Sources: A PubMed (1966–January 2007) search…”
Get full text

Systematic review of medication safety assessment methods by Meyer-Massetti, Carla, Cheng, Christine M, Schwappach, David L B, Paulsen, Lynn, Ide, Brigid, Meier, Christoph R, Guglielmo, B Joseph

“…The accuracy, efficiency, and efficacy of four commonly recommended medication safety assessment methodologies were systematically reviewed. Medical literature…”
Get full text

Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012 by Cheng, Christine M, Shin, Jaekyu, Guglielmo, B Joseph

Get more information

A review of three stand-alone topical thrombins for surgical hemostasis by Cheng, Christine M., PharmD, Meyer-Massetti, Carla, MSc, Kayser, Steven R., PharmD

“…Abstract Background: Topical thrombins are active hemostatic agents that can be used to minimize blood loss during surgery. Before 2007, the only topical…”
Get full text

The FDA extended warning for intravenous haloperidol and torsades de pointes: How should institutions respond? by Meyer-Massetti, Carla, Cheng, Christine M, Sharpe, Bradley A, Meier, Christoph R, Guglielmo, B. Joseph

“…BACKGROUND: In September 2007, the Food and Drug Administration (FDA) strengthened label warnings for intravenous (IV) haloperidol regarding QT prolongation…”
Get full text

Cosmetic use of botulinum toxin type A in the elderly by Cheng, Christine M

“…Botulinum toxin type A injections are one of the most popular cosmetic procedures for diminishing the appearance of facial lines caused by habitual facial…”
Get full text

Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations by Cheng, Christine M., So, Thomas W., Bubp, Jeff L.

“…Background: The US Food and Drug Administration (FDA) recommends using only FDA-reviewed pharmacogenetic information to make prescribing decisions based on…”
Get full text

Boxed warning inconsistencies between drug information resources and the prescribing information by Cheng, Christine M, Fu, Carrie, Guglielmo, B Joseph, Auerbach, Andrew D

“…Inconsistencies in boxed warnings between drug information resources and the manufacturer's prescribing information (PI) were evaluated. This study was a…”
Get full text

Unlabeled uses of botulinum toxins: A review, part 1 by Cheng, Christine M, Chen, Jennifer S, Patel, Rosalie P

“…Efficacy and safety data regarding the unlabeled uses of botulinum toxins are reviewed, and the pharmacology, adverse effects, and characteristics of…”
Get full text

Unlabeled uses of botulinum toxins: A review, part 2 by Cheng, Christine M, Chen, Jennifer S, Patel, Rosalie P

“…Efficacy and safety data regarding the unlabeled uses of botulinum toxins are reviewed, and the pharmacology, adverse effects, and characteristics of…”
Get full text

Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs by Cheng, Christine M, Salazar, Alejandra, Amato, Mary G, Lambert, Bruce L, Volk, Lynn A, Schiff, Gordon D

“…To extract drug indications from a commercial drug knowledgebase and determine to what extent drug indications can discriminate between look-alike-sound-alike…”
Get full text

Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening Programs by Wang, Lorraine M, Wong, Maple, Lightwood, James M, Cheng, Christine M

“…BACKGROUND Black box warnings represent the strongest safety warning that the Food and Drug Administration can issue for a marketed prescription drug. Some…”
Get full text

Intrathecal Ziconotide for Refractory Chronic Pain by Lynch, Shalini S, Cheng, Christine M, Yee, Jennie L

“…To describe the pharmacology, efficacy, and safety of ziconotide for treatment of severe chronic pain in patients who are candidates for intrathecal therapy. A…”
Get full text

Pros and cons of dabigatran by Cheng, Christine M, McCurdy, Megan R, Wong, Heather A, Kayser, Steven R

Get full text

Coverage of FDA medication boxed warnings in commonly used drug information resources by Cheng, Christine M, Guglielmo, B Joseph, Maselli, Judy, Auerbach, Andrew D

Get more information

Simple Additions to the Pharmacy Waiting Area May Increase Patient Satisfaction by Cheng, Christine M.

Get full text

Lanthanum Carbonate Treatment of Hyperphosphatemia in End-Stage Renal Disease by Cheng, Christine M

“…Objective: To review the literature on the safety and efficacy of lanthanum carbonate for the treatment of hyperphosphatemia in patients with end-stage renal…”
Get full text

Content, Consistency, and Quality of Black Box Warnings by Cheng, Christine M., DeLizza, Colleen

Get full text

Full-length human recombinant parathyroid hormone for the treatment of osteoporosis by Cheng, Christine M, El-Ibiary, Shareen Y

“…Full-length or intact parathyroid hormone [rDNA origin] for injection (PTH [1-84], Preos, NPS Pharmaceuticals) is currently under FDA review for the treatment…”
Get full text

Formulary Forum: Intrathecal Ziconotide for Refractory Chronic Pain by Lynch, Shalini S, Cheng, Christine M, Yee, Jennie L

“…Objective: TO describe the pharmacology, efficacy, and safety of ziconotide for treatment of severe chronic pain in patients who are candidates for intrathecal…”
Get full text